Product Name:
NMDAR2A-pY943
Product Number:
ab-pn710
Target Full Name: Glutamate [NMDA] receptor subunit epsilon-1
Target Alias: Glutamate [NMDA] receptor subunit epsilon 1 precursor; Glutamate receptor, ionotropic, N-methyl D-aspartate 2A; NMDAR2A; NMDAR2AGlutamate [NMDA] receptor subunit epsilon 1; NMDE1; N-methyl D-aspartate receptor subtype 2A; N-methyl-D-aspartate receptor subtype 2A; NR2A
Product Type Specific: NMDAR2A (GRIN2A) calcium channel phosphosite-specific antibody
Antibody Code: PN710
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y943
Protein UniProt: Q12879
Protein SigNET: NMDAR2A
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human NMDAR2A
Antibody Immunogen Sequence: NLM(pY)SDN(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues N940 to N946. The effect of Y943 phosphorylation is unclear. This is the major in vivo phosphorylation site in NMDAR2A (≥134 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). This human phosphosite is highly conserved in vertebrates and also found in fish. NMDAR2A NMDA is known to be phosphorylated at this site in vitro by Fyn.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.5 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Dog | Rat | Mouse | Platypus | Frog | Zebra fish.
Related Product 1: NMDAR2A Y943 phosphorylation antibody (Cat. No.: AB-PN838)
Related Product 2: NMDAR2A Y1325 phosphorylation antibody (Cat. No.: AB-PN839)
Scientific Background: N-methyl-D-aspartate (NMDA) receptors are a class of ionotropic glutamate-gated ion channels in the brain that are crucial for synaptic plasticity, learning, and memory. They act as "coincidence detectors," requiring both glutamate binding and membrane depolarization to open, allowing calcium influx. These receptors have been shown to be involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission is believed to underlie certain kinds of memory and learning. NMDA receptor channels are heteromers composed of the key receptor subunit NMDAR1 (GRIN1) and 1 or more of the 4 NMDAR2 subunits: NMDAR2A (GRIN2A), NMDAR2B (GRIN2B), NMDAR2C (GRIN2C) and NMDAR2D (GRIN2D). At resting potentials, a magnesium ion (Mg2+) blocks the channel pore. When the neuron is depolarized (active) and glutamate/glycine binds, the Mg2+ is removed, allowing calcium and sodium ions to flow into the cell. Overstimulation can lead to excessive calcium influx, resulting in neuronal neurotoxicity (excitotoxicity) and cell death, commonly seen in stroke, Alzheimer's, and traumatic brain injury. Dysfunction of the NMDA receptor is also implicated in diseases such as schizophrenia, epilepsy, and depression. NMDA receptor antagonists (e.g., ketamine) are used in anesthesia and, at lower doses, show promise in treating severe depression. This description may include information annotated by UniProt and/or Google AI.